Clinical Trial of Vormatrigine in Adult Patients With Epilepsy
← catalyst calendarNCT07287163 · readout in 651 d
Sponsored by Praxis Precision Medicines (industry) · PRAX — their whole pipeline →.
Phase
Phase 3
Status
Enrolling by invitation
Study type
Interventional
Design
Na · None · Treatment
Enrollment
700estimated
Sites
36
Countries
Brazil, Germany, Italy +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-27 | actual | When the study began enrolling |
| Primary completion | 2028-05-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Epilepsy, Tonic-Clonic
- Focal Seizure
- Primary Generalized Seizure
Intervention
- Drug: vormatrogine
Primary outcomes
what the primary-completion date above is the date OFTo assess the safety and tolerability of vormatrigine in adults with focal or primary generalized tonic-clonic seizures
measured Up to 2 years
To assess the safety and tolerability of vormatrigine in adults with focal or primary generalized tonic-clonic seizures
measured Up to 2 years
To assess the safety and tolerability of vormatrigine in adults with focal or primary generalized tonic-clonic seizures
measured Up to 2 years
To assess the safety and tolerability of vormatrigine in adults with focal or primary generalized tonic-clonic seizures
measured Up to 2 years
To assess the safety and tolerability of vormatrigine in adults with focal or primary generalized tonic-clonic seizures
measured Up to 2 years
To assess the safety and tolerability of vormatrigine in adults with focal or primary generalized tonic-clonic seizures
measured Up to 2 years
To assess the safety and tolerability of vormatrigine in adults with focal or primary generalized tonic-clonic seizures
measured Up to 2 years
Permalink · PRAX's whole pipeline · Catalyst calendar · Every registered study · What changed